Is ketorolac ophthalmic (ketorolac) eye drop appropriate for children, and what age limit, dosing schedule, contraindications, and alternatives should be considered?

Ketorolac Ophthalmic Solution in Children

Ketorolac ophthalmic solution is FDA-approved for children ≥3 years of age and can be safely used for seasonal allergic conjunctivitis and postoperative inflammation following cataract surgery, but should be avoided in children with preexisting renal dysfunction, concurrent aspirin use, or single-ventricle cardiac palliation. 1

FDA-Approved Indications and Age Restrictions

• Minimum age: Safety and efficacy have been established only in children ≥3 years of age 1
• Approved indications:
  • Seasonal allergic conjunctivitis (ocular itching relief) 1
  • Postoperative inflammation following cataract extraction 1

Dosing Schedule

• Standard dosing: One drop (0.25 mg) four times daily for both approved indications 1
• Postoperative timing: Begin 24 hours after cataract surgery and continue through the first 2 weeks of the postoperative period 1
• Duration limits: Use beyond 14 days post-surgery increases risk of corneal adverse events 1

Critical Contraindications and Safety Concerns

High-Risk Pediatric Populations (Use with Extreme Caution)

Renal considerations:

• Ketorolac caused significant creatinine elevation in infants <6 months when administered systemically for 48 hours, though values remained within normal limits 2
• Absolute caution required in children with preexisting renal dysfunction 2
• Acute kidney injury risk increases with concomitant aspirin use 2
• Children with single-ventricle cardiac palliation are at increased risk for acute kidney injury 2

Ocular Safety Warnings

Corneal complications (sight-threatening):

• Continued NSAID use may cause epithelial breakdown, corneal thinning, erosion, ulceration, or perforation 1
• Immediately discontinue if corneal epithelial breakdown occurs 1
• High-risk conditions include:
  • Complicated ocular surgeries 1
  • Corneal denervation 1
  • Corneal epithelial defects 1
  • Diabetes mellitus 1
  • Ocular surface diseases (e.g., dry eye syndrome) 1
  • Rheumatoid arthritis 1
  • Repeat ocular surgeries within a short time period 1

Bleeding risk:

• Use with caution in children with known bleeding tendencies or receiving medications that prolong bleeding time 1
• However, a randomized trial in pediatric cardiac surgery did not show increased bleeding risk 2

Contact Lens Restriction

• Do not administer while wearing contact lenses 1

Alternatives for Pediatric Ocular Conditions

For Allergic Conjunctivitis (Safer First-Line Options)

Preferred antihistamines with broader age approval:

• Ketotifen: Approved for children ≥3 years; dosed twice daily 3
• Olopatadine: Approved for children ≥3 years; dosed twice daily for up to 4 months 3
• Azelastine hydrochloride: Approved for children ≥4 years; dosed 2-4 times daily 3

Mast cell stabilizer:

• Sodium cromoglycate: Approved for all pediatric ages; dosed 4 times daily 4

Initial therapy:

• Preservative-free ocular lubricants 2-4 times daily should be tried first 4

For Postoperative Inflammation

Corticosteroid options (when appropriate):

• Prednisolone acetate 1%: Superior corneal penetration for anterior segment inflammation 5
• Lower IOP-risk alternatives: Fluorometholone or loteprednol etabonate for patients requiring prolonged therapy 5

Common Pitfalls to Avoid

• Using in children <3 years: No safety or efficacy data exist for this age group 1
• Prolonged use >14 days post-surgery: Dramatically increases risk of severe corneal complications 1
• Starting >24 hours before surgery: Increases patient risk for corneal adverse events 1
• Ignoring renal function: Systemic ketorolac data show increased creatinine in infants <6 months, though ophthalmic absorption is minimal 2
• Combining with aspirin in high-risk cardiac patients: Significantly increases acute kidney injury risk 2
• Failure to monitor for corneal breakdown: Requires immediate discontinuation if detected 1

Clinical Context: Limited Pediatric Evidence

• A 2000 study in pediatric strabismus surgery found no analgesic benefit when ketorolac 0.5% ophthalmic solution was added to paracetamol, though this may reflect limitations in pain assessment tools rather than true lack of efficacy 6
• One preliminary study suggested potential benefit in preventing severe retinopathy of prematurity, but this was a weak observational design requiring confirmation in randomized trials 7
• A 1997 study in adults with corneal abrasions demonstrated significant reduction in pain, photophobia, and foreign body sensation compared to placebo, suggesting potential utility in pediatric corneal injury if age-appropriate 8